Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
December 14, 2017
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma
Laura Forker, Piers Gaunt, Stefano Sioletic, et al.
Cancer
|
August 9, 2011
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
Philippe A Cassier, Hans Gelderblom, Silvia Stacchiotti, et al.
BMJ Open
|
August 9, 2024
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol
Rita Simões, Sarah Gulliford, Beatrice Seddon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2016
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group
Stéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, et al.
Histopathology
|
August 19, 2010
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours
Marco Novelli, Sabrina Rossi, Manuel Rodriguez-Justo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)
Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
The Lancet. Oncology
|
September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Cancer
|
February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
The Lancet. Oncology
|
June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
Ian Judson, James P Morden, Lucy Kilburn, et al.
The Lancet. Oncology
|
August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
December 14, 2017
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma
Laura Forker, Piers Gaunt, Stefano Sioletic, et al.
Cancer
|
August 9, 2011
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
Philippe A Cassier, Hans Gelderblom, Silvia Stacchiotti, et al.
BMJ Open
|
August 9, 2024
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol
Rita Simões, Sarah Gulliford, Beatrice Seddon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2016
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group
Stéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, et al.
Histopathology
|
August 19, 2010
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours
Marco Novelli, Sabrina Rossi, Manuel Rodriguez-Justo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)
Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
The Lancet. Oncology
|
September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Cancer
|
February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
The Lancet. Oncology
|
June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
Ian Judson, James P Morden, Lucy Kilburn, et al.
The Lancet. Oncology
|
August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Page
of 4